Unwanted immunogenicity: Lessons learned and future challenges

Bioanalysis

Volumn 2, Issue 6, 2010, Pages 1073-1084

  Wadhwa, Meenu ^a,b   Thorpe, Robin ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b Cytokine and Growth Factor Section   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; ANTIBODY; DRUG;

ANTIBODY DETECTION; BINDING ASSAY; BIOASSAY; CELL ASSAY; CHEMOLUMINESCENCE; CLINICAL ASSESSMENT; ELECTROCHEMOLUMINESCENCE ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; LIGAND BINDING; PREDICTION; RADIOIMMUNOPRECIPITATION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SURFACE PLASMON RESONANCE; T LYMPHOCYTE; ANIMAL; DRUG EFFECT; IMMUNITY; IMMUNOLOGY;

ANIMALS; ANTIBODIES; BIOLOGICAL ASSAY; HUMANS; IMMUNITY; IMMUNOASSAY; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT;

EID: 79952473960     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.54     Document Type: Review

References (55)

1. Li J, Yang C, Xia Y, Bertino A et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98, 3241-3248 (2001).
2. Casadevall N, Nataf J, Viron B et al. Pure red cell aplasia and anti-erythropoietin antibodies against human erythropoietin in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346, 469-475 (2002). (Pubitemid 34441737)
3. Waters B, Lillicrap D. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J. Thromb. Haemost. 7(9), 1446-1456 (2009).
4. Wang J, Lozier J, Johnson G et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat. Biotechnol. 26(8), 901-908 (2008).
5. Baert F, Noman M, Vermiere S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348, 601-608 (2003). (Pubitemid 36204954)
6. Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3, 349-360 (2002). (Pubitemid 35364009)
7. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 357, 239-250 (2007). (Pubitemid 47080388)
8. Van Walle I, Gansemans Y, Parren PW et al. Immunogenicity screening in protein drug development. Expert Opin. Biol. Ther. 7, 405-418 (2007). (Pubitemid 46383483)
9. Rosenberg AS, Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products - part 1 - considering consequences of the immune response to a protein. Biopharm. Int. 17, 22-26 (2004). (Pubitemid 39573552)
10. Rosenberg AS, Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products - part 2 - considering host-specific and product specific factors impacting immunogenicity. Biopharm. Int. 17, 34-42 (2004). (Pubitemid 40013478)
11. Rosenberg AS, Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products - part 3 - effects of manufacturing changes in immunogenicity and the utility of animal immunogenicity studies. Biopharm. Int. 18, 32-36 (2005). (Pubitemid 40486131)
12. Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nature Biotechnol. 25, 555-561 (2007). (Pubitemid 46834844)
13. De Groot AS, Moise L, McMurry JA et al. Activation of natural regulatory T cells by IgG Fc-derived peptide 'tregitopes'. Blood 112(8), 3303-3311 (2008).
14. Barbosa MD, Vielmetter J, Chu S et al. Clinical link between MHC class II haplotype and interferon-b (IFN-b) immunogenicity. Clin. Immunol. 118(1), 42-50 (2006). (Pubitemid 43012045)
15. Kropshofer H, Singer T. Overview of cell-based tools for pre-clinical assessment of immunogenicity of biotherapeutics. J. Immunotoxicol. 3(3), 131-136 (2006). (Pubitemid 44266962)
16. Wadhwa M, Bird C, Dilger P et al. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J. Immunol. Methods 278, 1-17 (2003). (Pubitemid 37281188)
17. Klakamp SL, Lu H, Tabrizi M et al. Application of analytical detection concepts to immunogenicity testing. Anal. Chem. 79, 8176-8184 (2007). (Pubitemid 350060015)
18. Wadhwa M, Thorpe R. Strategies and assays for the assessment of unwanted immunogenicity. J. Immunotoxicol. 3, 115-121 (2006). (Pubitemid 44266960)
19. Patton A, Mullenix MC, Swanson SJ et al. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J. Immunol. Methods 304,189-195 (2005). (Pubitemid 41262233)
20. Bourdage JS, Cook CA, Farrington DL et al. An affinity capture elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J. Immunol. Methods 327, 10-17 (2007). (Pubitemid 47444307)
21. Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289, 1-16 (2004). (Pubitemid 38900899)
22. Schmidt E, Hennig K, Mengede C et al. Immunogenicity of rituximab in patients with severe pemphigus. Clin. Immunol. 132(3), 334-341 (2009).
23. Brickelmaier M, Hochman PS, Baciu R et al. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-b. J. Immunol. Methods 227, 121-135 (1999). (Pubitemid 29408710)
24. Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr. Opin. Immunol. 20(4), 431-435 (2008).
25. Gross J, Moller R, Henke W et al. Detection of anti-EPO antibodies in human sera by a bridging ELISA is much more sensitive when coating biotinylated rhEPO to streptavidin rather than using direct coating of rhEPO. J. Immunol. Methods 313, 176-182 (2006).
26. Tacey R, Greway A, Smiell J et al. The detection of anti-erythropoietin antibodies in human serum and plasma: part I. Validation of the protocol for a radioimmunoprecipitation assay. J. Immunol. Methods 283, 317-329 (2003). (Pubitemid 37501079)
27. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66, 921-926 (2007). (Pubitemid 46999794)
28. Thorpe R, Swanson SJ. Current methods for detecting antibodies against erythropoietin and other recombinant proteins. Clin. Diag. Lab. Immunol. 12, 28-39 (2005).
29. Swanson SJ. Characterization of an immune response. Dev. Biol. 122, 95-101 (2005). (Pubitemid 43002212)
30. Lofgren JA, Dhandapani S, Pennucci JJ et al. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J. Immunol. 178, 7467-7472 (2007). (Pubitemid 46847475)
31. Wadhwa M, Rini B, Bird C et al. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived GM-CSF. Cytokine 29, 56-66 (2005). (Pubitemid 39626637)
32. Rich RL, Myszka DG. Survey of the year 2007 commercial optical biosensor literature. J. Mol. Recognit. 21(6), 355-400 (2008).
33. Moxness M, Tatarewicz S, Weeraratne D et al. Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. Clin. Chem. 51, 1983-1985 (2005). (Pubitemid 41368199)
34. Marchese RD, Puchalski D, Miller P et al. Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serum. Clin. Vaccine Immunol. 16(3), 387-396 (2009).
35. Liang M, Klakamp SL, Funelas C et al. Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms. Assay Drug Dev. Technol. 5, 655-662 (2007).
36. Gupta S, Indelicato SR, Jethwa V et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods 321, 1-18 (2007). (Pubitemid 46454303)
37. Wei X, Swanson SJ, Gupta S. Development and validation of a cell-based bioassay for the detection of neutralizing antibodies against recombinant human erythropoietin in clinical studies. J. Immunol. Methods 293, 115-126 (2004). (Pubitemid 39468337)
38. Bertolotto A, Sala A, Caldano M et al. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-b. J. Immunol. Methods 321(1-2), 19-31 (2007). (Pubitemid 46441209)
39. Yu Y, Piddington C, Fitzpatrick D et al. A novel method for detecting neutralizing antibodies against therapeutic proteins by measuring gene expression. J. Immunol. Methods 316(1-2), 8-17 (2006). (Pubitemid 44573211)
40. Hu J, Gupta S, Swanson SJ et al. A bioactive drug quantitation based approach for the detection of anti-drug neutralizing antibodies in human serum. J. Immunol. Methods 345(1-2), 70-79 (2009).
41. Kitamura T, Tange T, Terasawa T et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J. Cell. Physiol. 140, 323-334 (1989). (Pubitemid 19185998)
42. Kelley M, Cooper C, Matticoli A et al. The detection of anti-erythropoietin antibodies in human serum and plasma Part II. Validation of a semi-quantitative 3H-thymidine uptake assay for neutralizing antibodies. J. Immunol. Methods 300, 179-191 (2005). (Pubitemid 40805597)
43. Moore M, Meager A, Wadhwa M et al. Measurement of neutralising antibodies to type I interferons by gene expression assays specific for type 1 interferon-inducible 6-16 mRNA. J. Pharm. Biomed. Anal. 49, 534-539 (2009).
44. Lallemand CJ, Meritet F, Erickson R et al. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene. J. Interferon Cytokine Res. 28, 393-404 (2008). (Pubitemid 351929939)
45. Lofgren JA, Wala I, Koren E et al. Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. J. Immunol. Methods 308, 101-108 (2006). (Pubitemid 43107958)
46. Baltrukonis D, Finco-Kent D, Poirier M et al. Development and validation of a quasi-quantitative bioassay for neutralizing antibodies against CP-870893. J. Immunotoxicol. 3, 157-164 (2006). (Pubitemid 44266965)
47. Cludts I, Meager A, Thorpe R et al. Detection of neutralizing interleukin-17 antibodies in autoimmune polyendocrinopathy syndrome-1 (APS-1) patients using a novel non-cell based electrochemiluminescence assay. Cytokine 50(2), 129-37 (2010).
48. Giovannoni G, Munschauer FE 3rd, Deisenhammer F. Neutralising antibodies to interferon b during the treatment of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 73(5), 465-469 (2002). (Pubitemid 35246792)
49. Bertolotto A Neutralizing antibodies to interferon b: implications for the management of multiple sclerosis. Curr. Opin. Neurol. 17, 241-246 (2004). (Pubitemid 38720974)
50. Wadhwa M, Bird C, Fagerberg J et al. Production of neutralizing GM-CSF antibodies in carcinoma patients following GM-CSF combination therapy. Clin. Exp. Immunol. 104, 351-358 (1996). (Pubitemid 26139781)
51. Subramanyam M. Case study: immunogenicity of natalizumab. In:Biotechnology: Pharmaceutical Aspects Immunogenicity of Biopharmaceuticals (Volume VIII). Marco van der Weert, Eva Horn Moller (Eds).Springer, AAPS Press, NY, USA, 173-188 (2008).
52. Wadhwa M, Thorpe R. Unwanted immunogenicity: mplications for follow-on biologicals. Drug Inf. J. 41, 1-10 (2007). (Pubitemid 46146055)
53. Wadhwa M, Skog A-LH, Bird C et al. Immunogenicity of granulocyte- macrophage colony stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin. Cancer Res. 5, 1353-1361 (1999). (Pubitemid 29282939)
54. Tatarewicz SM, Wei X, Gupta S et al. Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. J. Clin. Immunol. 27(6), 620-627 (2007).
55. Gibbs E, Oger J. A biosensor-based characterization of the affinity maturation of the immune response against interferon-b and correlations with neutralizing antibodies in treated multiple sclerosis patients. J. Interferon Cytokine Res. 28(12), 713-723 (2008). (Pubitemid 352773934)